Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396

1.

High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.

Dorjee K, Sadutshang TD, Rana RS, Topgyal S, Phunkyi D, Choetso T, Chodon T, Parmar M, Singla R, Paster Z, Chaisson RE, Kaushal KC.

Indian J Tuberc. 2020 Jan;67(1):59-64. doi: 10.1016/j.ijtb.2019.08.005. Epub 2019 Aug 17.

PMID:
32192619
2.

Patient-incurred cost of inpatient treatment for Tuberculosis in rural Malawi.

Shin H, Ngwira LG, Tucker A, Chaisson RE, Corbett EL, Dowdy DW.

Trop Med Int Health. 2020 Feb 8. doi: 10.1111/tmi.13381. [Epub ahead of print]

PMID:
32034984
3.

The impact of bone marrow stromal antigen-2 (BST2) gene variants on HIV-1 control in black South African individuals.

Dias BDC, Paximadis M, Martinson N, Chaisson RE, Ebrahim O, Tiemessen CT.

Infect Genet Evol. 2020 Jan 30;80:104216. doi: 10.1016/j.meegid.2020.104216. [Epub ahead of print]

PMID:
32006707
4.

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium.

Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22.

PMID:
31981713
5.

Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV.

Abdelwahab MT, Leisegang R, Dooley KE, Mathad JS, Wiesner L, McIlleron H, Martinson N, Waja Z, Letutu M, Chaisson RE, Denti P.

Antimicrob Agents Chemother. 2020 Feb 21;64(3). pii: e01978-19. doi: 10.1128/AAC.01978-19. Print 2020 Feb 21.

PMID:
31844002
6.

CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV.

Chaisson LH, Saraceni V, Cohn S, Seabrook D, Cavalcante SC, Chaisson RE, Golub JE, Durovni B.

AIDS. 2020 Jan 1;34(1):139-147. doi: 10.1097/QAD.0000000000002398.

PMID:
31634189
7.

Isoniazid Preventive Therapy and Pregnancy Outcomes In HIV-Infected Women in the Tshepiso Cohort.

Salazar-Austin N, Cohn S, Lala S, Waja Z, Dooley KE, Hoffmann CJ, Chaisson RE, Martinson N; TSHEPISO Study Team .

Clin Infect Dis. 2019 Oct 21. pii: ciz1024. doi: 10.1093/cid/ciz1024. [Epub ahead of print]

PMID:
31631221
8.

Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.

Kendall EA, Durovni B, Martinson NA, Cavalacante S, Masonoke K, Saraceni V, Lebina L, Efron A, Cohn S, Chon S, Chaisson RE, Dowdy DW, Golub JE; THRio and TEKO teams.

AIDS. 2020 Jan 1;34(1):63-71. doi: 10.1097/QAD.0000000000002380.

PMID:
31567163
9.

Detection and molecular characterization of urinary tract HIV-1 populations.

Mzingwane ML, Hunt G, Lassauniere R, Kalimashe M, Bongwe A, Ledwaba J, Chaisson RE, Martinson N, Richter K, Bowyer SM, Tiemessen CT.

Ann Clin Microbiol Antimicrob. 2019 Sep 24;18(1):27. doi: 10.1186/s12941-019-0326-9.

10.

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.

Chaisson RE, Ramchandani R, Swindells S.

N Engl J Med. 2019 Sep 12;381(11):e23. doi: 10.1056/NEJMc1908492. No abstract available.

PMID:
31509690
11.

Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.

Miyahara S, Ramchandani R, Kim S, Evans SR, Gupta A, Swindells S, Chaisson RE, Montepiedra G.

Clin Infect Dis. 2020 Feb 3;70(4):698-703. doi: 10.1093/cid/ciz784.

PMID:
31414121
12.

Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE.

Am J Epidemiol. 2019 Dec 31;188(12):2078-2085. doi: 10.1093/aje/kwz172.

PMID:
31364692
13.

Improving TPT Uptake: A Cluster-Randomized Trial of Symptom-Based Versus Tuberculin Skin Test-Based Screening of Household Tuberculosis Contacts Less than 5 Years of Age.

Salazar-Austin N, Cohn S, Barnes GL, Tladi M, Motlhaoleng K, Swanepoel C, Motala Z, Variava E, Martinson N, Chaisson RE.

Clin Infect Dis. 2019 May 24. pii: ciz436. doi: 10.1093/cid/ciz436. [Epub ahead of print]

PMID:
31127284
14.

Cis-regulatory genetic variants in the CCR5 gene and natural HIV-1 control in black South Africans.

Koor GW, Paximadis M, Picton ACP, Karatas F, Loubser SA, He W, Ahuja SK, Chaisson RE, Martinson N, Ebrahim O, Tiemessen CT.

Clin Immunol. 2019 Aug;205:16-24. doi: 10.1016/j.clim.2019.05.009. Epub 2019 May 15.

PMID:
31100442
15.

Addressing critical needs in the fight to end tuberculosis with innovative tools and strategies.

Hatherill M, Chaisson RE, Denkinger CM.

PLoS Med. 2019 Apr 30;16(4):e1002795. doi: 10.1371/journal.pmed.1002795. eCollection 2019 Apr.

16.

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, Jain S, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00388-19. doi: 10.1128/AAC.00388-19. Print 2019 Jun.

17.

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team.

N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808.

18.

The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression.

Lassaunière R, Paximadis M, Ebrahim O, Chaisson RE, Martinson NA, Tiemessen CT.

Genes Immun. 2019 Nov;20(8):651-659. doi: 10.1038/s41435-018-0053-9. Epub 2018 Dec 19.

19.

High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children.

Dorjee K, Topgyal S, Dorjee C, Tsundue T, Namdol T, Tsewang T, Nangsel T, Lhadon D, Choetso T, Dawa T, Phentok T, DeLuca AN, Tsering L, Phunkyi D, Sadutshang TD, J Bonomo E, Paster Z, Chaisson RE.

Clin Infect Dis. 2019 Aug 16;69(5):760-768. doi: 10.1093/cid/ciy987.

20.

Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics Guidance.

Denholm JT, Silva DS, Burhan E, Chaisson RE.

Trop Med Infect Dis. 2018 Oct 31;3(4). pii: E115. doi: 10.3390/tropicalmed3040115.

21.

Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa).

Ngwira LG, Corbett EL, Khundi M, Barnes GL, Nkhoma A, Murowa M, Cohn S, Moulton LH, Chaisson RE, Dowdy DW.

Clin Infect Dis. 2019 Mar 19;68(7):1176-1183. doi: 10.1093/cid/ciy590.

22.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF, Guo H, Chang YS, Li SY, Tapley A, Tasneen R, Tyagi S, Betoudji F, Moodley C, Ngcobo B, Pillay L, Bester LA, Singh SD, Chaisson RE, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00636-18. doi: 10.1128/AAC.00636-18. Print 2018 Jul.

23.

An Education and Field Experience Program to Increase Detection of Human Immunodeficiency Virus and Hepatitis C Virus.

Irvin R, McAdams-Mahmoud A, White JJ, Grant Z, Falade-Nwulia O, Sherman SG, Beyrer C, Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE.

Prog Community Health Partnersh. 2018;12(1):101-109. doi: 10.1353/cpr.2018.0011.

24.

Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.

Little KM, Khundi M, Barnes GL, Ngwira LG, Nkhoma A, Makombe S, Corbett EL, Chaisson RE, Dowdy DW.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):371-377. doi: 10.5588/ijtld.16.0836.

25.

Delay in seeking care for tuberculosis symptoms among adults newly diagnosed with HIV in rural Malawi.

Ngwira LG, Dowdy DW, Khundi M, Barnes GL, Nkhoma A, Choko AT, Murowa M, Chaisson RE, Corbett EL, Fielding K.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):280-286. doi: 10.5588/ijtld.17.0539.

26.

Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.

Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR.

Ann Am Thorac Soc. 2018 May;15(5):570-580. doi: 10.1513/AnnalsATS.201704-326OC.

27.

Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study.

Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, Hoffmann C, Dooley KE, Chaisson RE, Martinson N; TSHEPISO Study Team.

Clin Infect Dis. 2018 Mar 5;66(6):921-929. doi: 10.1093/cid/cix851.

28.

Preventing tuberculosis in people with HIV-no more excuses.

Chaisson RE, Golub JE.

Lancet Glob Health. 2017 Nov;5(11):e1048-e1049. doi: 10.1016/S2214-109X(17)30390-X. No abstract available.

29.

Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients.

Adu-Gyamfi CG, Snyman T, Hoffmann CJ, Martinson NA, Chaisson RE, George JA, Suchard MS.

Clin Infect Dis. 2017 Oct 15;65(8):1356-1358. doi: 10.1093/cid/cix550.

30.

Factors associated with pulmonary impairment in HIV-infected South African adults.

Gupte AN, Wong ML, Msandiwa R, Barnes GL, Golub J, Chaisson RE, Hoffmann CJ, Martinson NA.

PLoS One. 2017 Sep 13;12(9):e0184530. doi: 10.1371/journal.pone.0184530. eCollection 2017.

31.

CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals.

Picton ACP, Paximadis M, Chaisson RE, Martinson NA, Tiemessen CT.

Clin Immunol. 2017 Jul;180:69-79. doi: 10.1016/j.clim.2017.04.006. Epub 2017 Apr 18.

32.

Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.

McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE; Tshepiso Study Team.

J Antimicrob Chemother. 2017 Jul 1;72(7):2028-2034. doi: 10.1093/jac/dkx112.

33.

Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial.

Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S.

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):286-296. doi: 10.5588/ijtld.16.0469. Epub 2017 Jan 13.

34.

RICH2 is implicated in viraemic control of HIV-1 in black South African individuals.

Paximadis M, Ngqobe RN, Chaisson RE, Martinson NA, Tiemessen CT.

Infect Genet Evol. 2017 Apr;49:78-87. doi: 10.1016/j.meegid.2017.01.007. Epub 2017 Jan 6.

35.

Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis.

Alipanah N, Cattamanchi A, Menzies R, Hopewell PC, Chaisson RE, Nahid P.

Int J Tuberc Lung Dis. 2016 Nov;20(11):1522-1528. Review.

PMID:
27776595
36.

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):853-67. doi: 10.1093/cid/ciw566.

37.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.

38.

Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.

Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17.

AIDS. 2016 Jun 19;30(10):1607-15. doi: 10.1097/QAD.0000000000001098.

39.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.

40.

Improved Detection of Tuberculosis and Multidrug-Resistant Tuberculosis among Tibetan Refugees, India.

Dierberg KL, Dorjee K, Salvo F, Cronin WA, Boddy J, Cirillo D, Sadutshang T, Chaisson RE.

Emerg Infect Dis. 2016 Mar;22(3):463-8. doi: 10.3201/eid2203.140732.

41.

Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa.

Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H, Dooley KE.

Antimicrob Agents Chemother. 2015 Dec 7;60(3):1234-41. doi: 10.1128/AAC.02051-15.

42.

Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?

Lanoix JP, Chaisson RE, Nuermberger EL.

Clin Infect Dis. 2016 Feb 15;62(4):484-90. doi: 10.1093/cid/civ911. Epub 2015 Nov 1.

43.

Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection.

Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, Chaisson RE.

Lancet. 2015 Dec 5;386(10010):2344-53. doi: 10.1016/S0140-6736(15)00323-2. Epub 2015 Oct 26. Review. Erratum in: Lancet. 2015 Dec 5;386(10010):2256.

44.

Undiagnosed TB in adults dying at home from natural causes in a high TB burden setting: a post-mortem study.

Omar T, Variava E, Moroe E, Billioux A, Chaisson RE, Lebina L, Martinson N.

Int J Tuberc Lung Dis. 2015 Nov;19(11):1320-5. doi: 10.5588/ijtld.15.0222.

PMID:
26467584
45.

Latent tuberculous infection in schoolchildren and contact tracing in Matlosana, North West Province, South Africa.

Lebina L, Abraham PM, Milovanovic M, Motlhaoleng K, Chaisson RE, Rakgokong M, Golub J, Variava E, Martinson NA.

Int J Tuberc Lung Dis. 2015 Nov;19(11):1290-2. doi: 10.5588/ijtld.15.0370.

46.

Integrated Source Case Investigation for Tuberculosis (TB) and HIV in the Caregivers and Household Contacts of Hospitalised Young Children Diagnosed with TB in South Africa: An Observational Study.

Lala SG, Little KM, Tshabangu N, Moore DP, Msandiwa R, van der Watt M, Chaisson RE, Martinson NA.

PLoS One. 2015 Sep 17;10(9):e0137518. doi: 10.1371/journal.pone.0137518. eCollection 2015.

47.

Latent Mycobacterium tuberculosis Infection.

Getahun H, Chaisson RE, Raviglione M.

N Engl J Med. 2015 Sep 17;373(12):1179-80. doi: 10.1056/NEJMc1508223. No abstract available.

PMID:
26376149
48.

Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa.

Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, Haas DW, Dooley KE, Martinson NA, Chaisson RE.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):31-7. doi: 10.1097/QAI.0000000000000811.

49.

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.

Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Kim P, Fletcher CV; AIDS Clinical Trials Group A5279 Study Team.

Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16.

50.

Correction: CD4 and Viral Load Dynamics in Antiretroviral-Naïve HIV-Infected Adults from Soweto, South Africa: A Prospective Cohort.

Martinson NA, Gupte N, Msandiwa R, Moulton LH, Barnes GL, Ram M, Gray G, Hoffmann C, Chaisson RE.

PLoS One. 2015 Jun 10;10(6):e0130509. doi: 10.1371/journal.pone.0130509. eCollection 2015. No abstract available.

Supplemental Content

Loading ...
Support Center